Abstract
Recently, guidelines have been outlined for management of immune-related adverse events occurring with immune checkpoint inhibitors in cancer, irrespective of affected organ systems. Increasingly, these complications have been recognized as including diverse neuromuscular presentations, such as demyelinating and axonal length-dependent peripheral neuropathies, vasculitic neuropathy, myasthenia gravis, and myopathy. We present 2 cases of brachial plexopathy developing on anti-programmed cell death-1 checkpoint inhibitor therapies (pembrolizumab, nivolumab). Both cases had stereotypic lower-trunk brachial plexus-predominant onsets, and other clinical features distinguishing them from Parsonage-Turner syndrome (ie, idiopathic plexitis). Each case responded to withholding of anti-programmed cell death-1 therapy, along with initiation of high-dose methylprednisiolone therapy. However, both patients worsened when being weaned from corticosteroids. Discussed are the complexities in the decision to add a second-line immunosuppressant drug, such as infliximab, when dealing with neuritis attacks, for which improvement may be prolonged, given the inherent slow recovery seen with axonal injury. Integrated care with oncology and neurology i...Continue Reading
References
Aug 1, 1972·Archives of Neurology·P TsairisD W Mulder
Feb 1, 1996·Neurology·G A SuarezP J Dyck
Dec 2, 1999·Nature Medicine·H DongL Chen
Jul 2, 2002·Nature Medicine·Haidong DongLieping Chen
Sep 28, 2007·International Immunology·Raymond M WongJeffrey S Weber
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Nov 10, 2010·Nature Reviews. Neurology·Guido Cavaletti, Paola Marmiroli
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Apr 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T W ChenA R Hansen
Feb 24, 2016·International Journal of Clinical Oncology·Junzo HamanishiIkuo Konishi
Mar 2, 2016·Annual Review of Immunology·Susanne H BaumeisterArlene H Sharpe
Mar 5, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Hélène ValletDimitri Psimaras
Apr 17, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lisa ZimmerLucie M Heinzerling
Apr 20, 2016·The New England Journal of Medicine·Paul T NghiemMartin A Cheever
Apr 27, 2016·Handbook of Clinical Neurology·Christopher J Klein
Apr 29, 2016·Muscle & Nerve·Pinar Polat, Peter D Donofrio
Jul 29, 2016·The New England Journal of Medicine·Marie-Florence de MaleissyePhilippe Saiag
Nov 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F AyaA Arance
Dec 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C L HaddoxM P Goetz
Feb 24, 2017·Frontiers in Pharmacology·Vivek KumarAbhinav B Chandra
Citations
Jul 22, 2019·The British Journal of Dermatology·T GambichlerI Ayzenberg
Aug 21, 2019·Leukemia & Lymphoma·Zhengrui XiaoIoannis Mantzaris
Mar 14, 2020·Journal of the Peripheral Nervous System : JPNS·Jordi BrunaHaralabos P Kalofonos
Aug 9, 2019·Journal of the Peripheral Nervous System : JPNS·Dimitri PsimarasAndreas A Argyriou
Oct 13, 2020·Curēus·Hassan Kesserwani
Aug 17, 2020·Neurology·Elia SechiAnastasia Zekeridou
Nov 15, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Elia Sechi, Anastasia Zekeridou
Feb 20, 2021·ENeurologicalSci·Saskia BolzTim Hagenacker
Feb 10, 2020·The Medical Clinics of North America·Cristina Kline-QuirozMichael D Stubblefield
Aug 31, 2021·SAGE Open Medical Case Reports·Yolanda PiñaEdwin Peguero